Message from

QiPharma R&D Japan
(Quick Impact Pharma R&D Japan)

Saving the lead time for “Go/ No-Go” decisions at each stage of product development in Japan eventually resulting in abbr. NDA approaches

Offering drug development plans/ options/ strategies in Japan different from those within and outside a company

Providing cost-effective assistance (extensive research/ report at low cost) for robust drug development plans together with a wide variety of development-related information from Japanese regulatory authorities or academia